Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BMS-986218 + Nivolumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BMS-986218||BMS986218|BMS 986218||CTLA4 Antibody 24 Immune Checkpoint Inhibitor 153||BMS-986218 is a 2nd generation antibody that targets CTLA4, resulting in T-cell activation and increased anti-tumor immune response (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B33).|
|Nivolumab||Opdivo||MDX-1106|BMS-936558||Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 100||Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) in patients with melanoma, renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, in combination with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent NSCLC without EGFR or ALK alterations, in combination with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, in combination with Cabometyx (cabozantinib) in patients with advanced renal cell carcinoma, and in combination with fluoropyrimidine- and platinum-containing chemotherapy in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03110107||Phase Ib/II||Ipilimumab BMS-986218 + Nivolumab BMS-986218||First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors||Active, not recruiting||USA | ITA | FRA | ESP | DEU | CAN | BEL||10|
|NCT05169684||Phase II||BMS-986218 + Docetaxel Docetaxel BMS-986218 + Nivolumab BMS-986218 + Docetaxel + Nivolumab||A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer||Recruiting||USA | ITA | FRA | ESP | CAN||5|
|NCT04785287||Phase Ib/II||BMS-986218 BMS-986218 + Nivolumab||Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies||Active, not recruiting||USA||0|